Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656566.9.13.2363
Reference42 articles.
1. Acquired Immune Deficiency Syndrome in the United States: The First 1,000 Cases
2. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
3. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
4. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2);Applied Sciences;2023-03-31
2. Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance;Bioengineering;2022-07-25
3. Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels;International Journal of Molecular Sciences;2022-05-18
4. Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study;Pediatric Drugs;2022-04-16
5. The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection.;Acta Biomedica Scientifica;2021-12-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3